StockDriftsStockDriftsTop 2 Regeneron Pharmaceuticals INC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | 35.35% | 3.70M | $62.7M | +0.00%(+0) | $16.10(-26.30%) | 2026-06-30 | |
| ACET | Adicet Bio, Inc. | 0.3% | 60.5K | $523K | +0.00%(+0) | $19.22(-58.01%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (6 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +201.38% |
| Top 20 Holdings Unweighted | — | — | — | — | +54.66% |
Regeneron Pharmaceuticals INC reports $177.22M in US-listed equity holdings across 3 positions in its most recent 13F filing. Its largest disclosed positions are NTLA (35.4%) and ACET (0.3%). The top 20 holdings account for 35.65% of reported assets. Its disclosed equity book has returned +201.38% cumulatively over 6 quarters. Figures reflect the Q2 2026 filing.
Sign up free to track Regeneron Pharmaceuticals INC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Regeneron Pharmaceuticals INC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 872589). View Regeneron Pharmaceuticals INC’s 13F filings on SEC